Tower Research Capital LLC (Trc) Nuvalent, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,964 shares of NUVL stock, worth $189,526. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,964
Previous 3,142
37.49%
Holding current value
$189,526
Previous $239,000
29.29%
% of portfolio
0.0%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding NUVL
# of Institutions
213Shares Held
61.4MCall Options Held
35.1KPut Options Held
62.2K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.74 Billion28.96% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$509 Million14.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$444 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$292 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA2.3MShares$222 Million0.04% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.15B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...